Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention (Q38007893)

26 August 2017

title

Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention (English)

1 reference

26 August 2017

author name string

Maria M Patarroyo Aponte

series ordinal

1

1 reference

26 August 2017

Gary S Francis

series ordinal

2

1 reference

26 August 2017

publication date

1 August 2012

1 reference

Current cardiology reports

26 August 2017

published in

1 reference

26 August 2017

volume

14

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

433-442

1 reference

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini-pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Effects of digoxin, furosemide, enalaprilat and metoprolol on endothelial function in young normotensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Chronic ACE inhibition enhances the endothelial control of arterial mechanics and flow-dependent vasodilatation in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

The tissue renin-angiotensin system and intracellular signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

High tissue affinity angiotensin-converting enzyme inhibitors improve endothelial function and reduce infarct size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Effects of ACE inhibitors on cardiac angiotensin II and aldosterone in humans: "Relevance of lipophilicity and affinity for ACE".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Vascular protection in peripheral artery disease: systematic review and modelling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0275-9

Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure

21 January 2018

1 reference

12 December 2020

Coronary artery atherosclerosis revisited in Korean war combat casualties

1 reference

12 December 2020

Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis

1 reference

12 December 2020

Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia

1 reference

12 December 2020

Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes

1 reference

12 December 2020

Q: Is an ACE inhibitor plus an ARB more effective than either drug alone?

1 reference

12 December 2020

Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit

1 reference

12 December 2020

Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril

1 reference

12 December 2020

Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives

1 reference

12 December 2020

Effects of captopril on atherosclerosis in cynomolgus monkeys

1 reference

12 December 2020

Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan

1 reference

12 December 2020

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

1 reference

12 December 2020

Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial

1 reference

12 December 2020

Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients

1 reference

12 December 2020

Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury

1 reference

12 December 2020

Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: a randomized, double-blind study

1 reference

12 December 2020

Impact of Telmisartan Versus Ramipril on Renal Endothelial Function in Patients With Hypertension and Type 2 Diabetes

1 reference

12 December 2020

10.1007/S11886-012-0275-9

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1037590132

0 references

1 reference